Dr. Paika Podcast

#LDL #Cholesterol #LowerCholesterol #GLP1 #HeartHealth

Can you lower LDL cholesterol without a statin? Yes, by roughly 10–15% in real life, and more if you're strict. I'm Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine. In this video I show you which foods actually lower LDL, how much each one does, and when food alone isn't enough.

FREE GLP-1 Diet Cookbook (200 recipes, protein and fiber listed for every serving): https://drmohammedpaika.com/newsletter
GLP-1 Masterclass (protein targets + 12-week home exercise program): https://drmohammedpaika.com

TIMESTAMPS
0:00 Food vs a statin: what one study found
1:09 Who this video is for
1:26 My LDL story
2:12 Why a modest LDL drop matters
2:51 The Portfolio diet study (and the catch)
4:19 Step 1: Swap saturated fat for unsaturated fat
5:23 Coconut oil and eggs
6:03 Low-carb diets and LDL
6:31 Step 2: Soluble fiber
7:59 Step 3: Plant sterols and stanols
8:57 Free GLP-1 Diet Cookbook
9:25 Step 4: Nuts
10:01 Step 5: Soy protein
10:39 Step 6: Coffee, weight loss, and exercise
11:22 What I see in the hospital
13:08 When food isn't enough: LDL 190 or higher
13:37 High lipoprotein(a)
14:01 High overall risk
14:32 Heart disease or diabetes
14:50 Red yeast rice and supplements
16:37 If statins don't agree with you
17:38 GLP-1s and the SELECT trial
18:23 When to recheck your lipids
18:37 Summary: the plan in 30 seconds
19:35 If you're on a GLP-1

REFERENCES
1. Jenkins 2003, JAMA: https://pubmed.ncbi.nlm.nih.gov/12876093/
2. Jenkins 2011, JAMA: https://pubmed.ncbi.nlm.nih.gov/21862744/
3. Chiavaroli 2018, Prog Cardiovasc Dis: https://pubmed.ncbi.nlm.nih.gov/29807048/
4. Ference 2017, Eur Heart J: https://pubmed.ncbi.nlm.nih.gov/28444290/
5. CTT 2010, Lancet: https://pubmed.ncbi.nlm.nih.gov/21067804/
6. Grundy 2018 guideline, Circulation: https://pubmed.ncbi.nlm.nih.gov/30586774/
7. Sacks 2017, AHA advisory, Circulation: https://pubmed.ncbi.nlm.nih.gov/28620111/
8. Hooper 2020, Cochrane: https://pubmed.ncbi.nlm.nih.gov/32428300/
9. Neelakantan 2020, Circulation: https://pubmed.ncbi.nlm.nih.gov/31928080/
10. Weggemans 2001, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/11333841/
11. Soto-Mota 2024, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/38237807/
12. Whitehead 2014, Am J Clin Nutr (industry-funded): https://pubmed.ncbi.nlm.nih.gov/25411276/
13. Jovanovski 2018, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/30239559/
14. Brown 1999, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/9925120/
15. Ras 2014, Br J Nutr (industry authors): https://pubmed.ncbi.nlm.nih.gov/24780090/
16. Gylling 2014, EAS consensus, Atherosclerosis: https://pubmed.ncbi.nlm.nih.gov/24468148/
17. Del Gobbo 2015, Am J Clin Nutr (part industry-funded): https://pubmed.ncbi.nlm.nih.gov/26561616/
18. Blanco Mejia 2019, J Nutr: https://pubmed.ncbi.nlm.nih.gov/31006811/
19. Jee 2001, Am J Epidemiol: https://pubmed.ncbi.nlm.nih.gov/11207153/
20. Urgert 1997, Annu Rev Nutr: https://pubmed.ncbi.nlm.nih.gov/9240930/
21. Dattilo 1992, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/1386186/
22. Mann 2014, Sports Med: https://pubmed.ncbi.nlm.nih.gov/24174305/
23. Blumenthal 2026 ACC/AHA dyslipidemia guideline, JACC: https://pubmed.ncbi.nlm.nih.gov/41824590/
24. Kronenberg 2022, EAS Lp(a) consensus, Eur Heart J: https://pubmed.ncbi.nlm.nih.gov/36036785/
25. Gerards 2015, Atherosclerosis: https://pubmed.ncbi.nlm.nih.gov/25897793/
26. Gordon 2010, Arch Intern Med: https://pubmed.ncbi.nlm.nih.gov/20975018/
27. Sekiguchi 2026, Kidney Int Rep: https://pubmed.ncbi.nlm.nih.gov/41732753/
28. Laffin 2023, SPORT, JACC (AstraZeneca-funded): https://pubmed.ncbi.nlm.nih.gov/36351465/
29. CTT 2022, Lancet: https://pubmed.ncbi.nlm.nih.gov/36049498/
30. Zhang 2013, Ann Intern Med: https://pubmed.ncbi.nlm.nih.gov/23546564/
31. Pandor 2009, J Intern Med: https://pubmed.ncbi.nlm.nih.gov/19141093/
32. Nissen 2023, CLEAR Outcomes, NEJM (Esperion-funded): https://pubmed.ncbi.nlm.nih.gov/36876740/
33. Sabatine 2017, FOURIER, NEJM (Amgen-funded): https://pubmed.ncbi.nlm.nih.gov/28304224/
34. Lincoff 2023, SELECT, NEJM (Novo Nordisk-funded): https://pubmed.ncbi.nlm.nih.gov/37952131/

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #GLP1 #WeightLoss #Wegovy #Mounjaro

Why do most people regain the weight after stopping Ozempic, Wegovy, Mounjaro or Zepbound? As a board-certified Internal Medicine and Obesity Medicine physician, I walk through the 5 reasons weight comes back: your metabolism, your hunger hormones, stopping the medication, your activity level and not watching the scale. For each one, I go through what the research actually shows, including the Biggest Loser follow-up studies, the STEP and SURMOUNT-4 trials and a 2026 BMJ review of 37 studies. Then I share the 5-step plan that gives you the best odds of keeping the weight off, plus my own story of losing 45 pounds, regaining it and losing it again.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

TIMESTAMPS
0:00 The Biggest Loser study
1:26 Who this video is for
2:08 My own regain story
3:45 Reason 1: Your metabolism slows down
4:53 Reason 2: Hunger hormones stay turned up
6:04 Reason 3: The medication stops
8:23 Free GLP-1 Diet Cookbook
9:01 Reason 4: Activity doesn't stay high enough
11:04 Reason 5: Nobody is watching the scale
12:48 The plan: 5 things that give you the best odds
15:57 The 30-second scorecard
16:45 GLP-1 Masterclass

REFERENCES
1. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016. https://pubmed.ncbi.nlm.nih.gov/27136388/
2. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011. https://pubmed.ncbi.nlm.nih.gov/22029981/
3. Wilding JPH, et al. Weight regain after withdrawal of semaglutide: STEP 1 trial extension. Diabetes Obes Metab. 2022. https://pubmed.ncbi.nlm.nih.gov/35441470/
4. Rubino D, et al. Continued semaglutide vs placebo for weight loss maintenance (STEP 4). JAMA. 2021. https://pubmed.ncbi.nlm.nih.gov/33755728/
5. Aronne LJ, et al. Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024. https://pubmed.ncbi.nlm.nih.gov/38078870/
6. West S, et al. Weight regain after cessation of medication for weight management. BMJ. 2026. https://pubmed.ncbi.nlm.nih.gov/41500720/
7. Kerns JC, et al. Increased physical activity associated with less weight regain six years after "The Biggest Loser." Obesity. 2017. https://pubmed.ncbi.nlm.nih.gov/29086499/
8. Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33951361/
9. Wing RR, et al. A self-regulation program for maintenance of weight loss (STOP Regain). N Engl J Med. 2006. https://pubmed.ncbi.nlm.nih.gov/17035649/
10. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005. https://pubmed.ncbi.nlm.nih.gov/16002825/
11. Jensen MD, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014. https://pubmed.ncbi.nlm.nih.gov/24222017/

This video is for education, not medical advice. Talk to your own doctor before making changes to your medication.

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#ozempic #glp1 #naturalozempic #berberine #weightloss

Do "natural Ozempic" foods actually work? I'm a board-certified internal medicine and obesity medicine physician, and I prescribe GLP-1 medications. In this video, I rank the 7 most popular natural Ozempic claims as real, partly real, or hype: apple cider vinegar, cinnamon, berberine, probiotics, healthy fats, eating order, protein first, and beans. You'll learn what each one can and can't do for your own GLP-1, what the human studies actually show, and which ones I use every day, whether you're on Ozempic, Wegovy, Mounjaro, or Zepbound or not.

FREE GLP-1 Diet Cookbook (200 recipes, protein and fiber per serving): https://drmohammedpaika.com/newsletter
GLP-1 Masterclass: https://drmohammedpaika.com

TIMESTAMPS
0:00 Do natural Ozempic foods work?
1:10 Why I don't trust shortcuts
2:06 Your body already makes GLP-1
3:19 #1 Apple cider vinegar & cinnamon
4:26 #2 Berberine
5:52 #3 Probiotics & fermented foods
7:09 #4 Healthy fats
8:22 #5 Eating order
9:22 #6 Protein first
10:52 #7 Beans & lentils
13:15 The honest answer
14:28 The scorecard

REFERENCES
Holst 2007 Physiol Rev: pubmed.ncbi.nlm.nih.gov/17928588
Drucker 2018 Cell Metab: pubmed.ncbi.nlm.nih.gov/29617641
Eissele 1992 Eur J Clin Invest: pubmed.ncbi.nlm.nih.gov/1499644
Mozaffarian 2025 Am J Clin Nutr (GLP-1 nutrition advisory): pubmed.ncbi.nlm.nih.gov/40450457
Ozempic prescribing information: novo-pi.com/ozempic.pdf
Wilding 2021 NEJM (STEP 1): pubmed.ncbi.nlm.nih.gov/33567185
Jastreboff 2022 NEJM (SURMOUNT-1): pubmed.ncbi.nlm.nih.gov/35658024
Wilding 2022 (STEP 1 extension): pubmed.ncbi.nlm.nih.gov/35441470
Johnston 2004 Diabetes Care (vinegar): pubmed.ncbi.nlm.nih.gov/14694010
Kondo 2009 (vinegar, weight): pubmed.ncbi.nlm.nih.gov/19661687
Liljeberg 1998 (vinegar, gastric emptying): pubmed.ncbi.nlm.nih.gov/9630389
Willershausen 2014 (vinegar, enamel): pubmed.ncbi.nlm.nih.gov/24839821
Allen 2013 Ann Fam Med (cinnamon): pubmed.ncbi.nlm.nih.gov/24019277
de Moura 2025 Nutr Rev (cinnamon): pubmed.ncbi.nlm.nih.gov/38917435
Hlebowicz 2009 (cinnamon, GLP-1): pubmed.ncbi.nlm.nih.gov/19158209
Abraham 2010 (coumarin): pubmed.ncbi.nlm.nih.gov/20024932
Yin 2008 Metabolism (berberine): pubmed.ncbi.nlm.nih.gov/18442638
Xie 2022 (berberine meta-analysis): pubmed.ncbi.nlm.nih.gov/36467075
Elahi Vahed 2026 Int J Obes (berberine, weight): pubmed.ncbi.nlm.nih.gov/41310257
Guo 2012 (berberine, CYP enzymes): pubmed.ncbi.nlm.nih.gov/21870106
Dumitru 2026 (berberine interactions): pubmed.ncbi.nlm.nih.gov/42653808
Tolhurst 2012 Diabetes (SCFA, GLP-1): pubmed.ncbi.nlm.nih.gov/22190648
Wastyk 2021 Cell (fermented foods): pubmed.ncbi.nlm.nih.gov/34256014
Depommier 2019 Nat Med (Akkermansia): pubmed.ncbi.nlm.nih.gov/31263284
Thomsen 1999 Am J Clin Nutr (olive oil): pubmed.ncbi.nlm.nih.gov/10357731
Carr 2008 (fat, protein, GLP-1): pubmed.ncbi.nlm.nih.gov/18612044
Wharton 2022 (GLP-1 GI side effects): pubmed.ncbi.nlm.nih.gov/34775881
Shukla 2015 Diabetes Care (food order): pubmed.ncbi.nlm.nih.gov/26106234
Shukla 2017 (carbs last, GLP-1): pubmed.ncbi.nlm.nih.gov/28989726
Jakubowicz 2014 Diabetologia (whey): pubmed.ncbi.nlm.nih.gov/25005331
Smedegaard 2023 (whey meta-analysis): pubmed.ncbi.nlm.nih.gov/37536867
Neeland 2024 (lean mass on GLP-1s): pubmed.ncbi.nlm.nih.gov/38937282
KDIGO 2024 (CKD guideline): pubmed.ncbi.nlm.nih.gov/38490803
Chambers 2015 Gut (propionate): pubmed.ncbi.nlm.nih.gov/25500202
Nilsson 2013 PLoS One (beans): pubmed.ncbi.nlm.nih.gov/23577078
Li 2014 Obesity (pulses, satiety): pubmed.ncbi.nlm.nih.gov/24820437
Kim 2016 Am J Clin Nutr (pulses, weight): pubmed.ncbi.nlm.nih.gov/27030531
Winham 2011 Nutr J (beans, gas): pubmed.ncbi.nlm.nih.gov/22104320
Duyff 2011 (rinsing canned beans): doi.org/10.1080/15428052.2011.582405
USDA FoodData Central: fdc.nal.usda.gov
IOM Dietary Reference Intakes 2005: doi.org/10.17226/10490

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Zepbound #VitaminDeficiency #WeightLoss

Taking Ozempic, Wegovy, Mounjaro, or Zepbound exactly as prescribed and still feeling more tired than you expected, noticing your hair shedding, or wondering if a multivitamin is enough?

In one trial, people on semaglutide ate about 35% less at an all-you-can-eat lunch. That's why these drugs work, but less food also means less protein, fiber, vitamins, and minerals unless you choose what's left on purpose.

In this video, I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. I break down 6 nutrients you can run low on with GLP-1 medications, how strong the evidence really is for each one, and what to do about it. You'll also get a simple lab checklist to discuss with your doctor, plus the rare deficiency (#6) that can put you in the hospital.

🍳 FREE GLP-1 Diet Cookbook (200 recipes, protein and fiber listed for every serving): https://drmohammedpaika.com/newsletter
🎓 GLP-1 Masterclass (protein targets, side effects, 12-week home exercise program, what happens when you stop, plus new modules on nausea, constipation, diarrhea, heartburn, and fatigue): https://drmohammedpaika.com
📩 Questions: support@drmohammedpaika.com

⏱️ TIMESTAMPS
0:00 Eating less on a GLP-1? Here's the problem
1:25 Why nutrients run low on these drugs
2:15 #1 Protein: protecting your muscle
3:23 #2 Fiber and constipation
4:12 #3 Vitamin D
5:36 Free GLP-1 Diet Cookbook
6:05 #4 Calcium and your bones
7:17 #5 Vitamin B12 (if you take metformin)
8:18 Iron, magnesium, and zinc: reality check
9:18 Hair loss: real, and usually temporary
10:15 #6 Thiamine (B1) and Wernicke encephalopathy
11:43 Red flags: when to call your doctor or go to the ER
12:29 Your lab checklist
13:50 Pregnancy and birth control on GLP-1s
14:26 GLP-1 Masterclass

📚 REFERENCES
1. Friedrichsen M, et al. Diabetes Obes Metab. 2021;23:754-62. https://pubmed.ncbi.nlm.nih.gov/33269530/
2. Butsch WS, et al. Obes Pillars. 2025;15:100186. https://pubmed.ncbi.nlm.nih.gov/40584822/
3. Look M, et al. (SURMOUNT-1 body composition) Diabetes Obes Metab. 2025;27:2720-9. https://pubmed.ncbi.nlm.nih.gov/39996356/
4. Wilding JPH, et al. (STEP 1) N Engl J Med. 2021;384:989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
5. Mozaffarian D, et al. (ACLM/ASN/OMA/TOS advisory) Am J Clin Nutr. 2025;122:344-67. https://pubmed.ncbi.nlm.nih.gov/40450457/
6. Johnson B, et al. Front Nutr. 2025;12:1566498. https://pubmed.ncbi.nlm.nih.gov/40352260/
7. Wortsman J, et al. Am J Clin Nutr. 2000;72:690-3. https://pubmed.ncbi.nlm.nih.gov/10966885/
8. Lai CH, et al. Arch Osteoporos. 2026;21. https://pubmed.ncbi.nlm.nih.gov/42920024/
9. Beaudart C, et al. Drugs. 2026;86:1661-91. https://pubmed.ncbi.nlm.nih.gov/42730869/
10. Aroda VR, et al. (Diabetes Prevention Program) J Clin Endocrinol Metab. 2016;101:1754-61. https://pubmed.ncbi.nlm.nih.gov/26900641/
11. ADA Standards of Care in Diabetes—2026, Section 3. Diabetes Care. 2026;49(Suppl 1):S50-S60. https://pubmed.ncbi.nlm.nih.gov/41358891/
12. Alhamdan Y, et al. Diabetes Obes Metab. 2026;28:5163-73. https://pubmed.ncbi.nlm.nih.gov/41913529/
13. Shao SC, et al. PLoS Med. 2026;23:e1004968. https://pubmed.ncbi.nlm.nih.gov/41790761/
14. Kanai R, et al. Obes Pillars. 2024;9:100098. https://pubmed.ncbi.nlm.nih.gov/38230266/
15. Gras C, et al. Eur J Clin Nutr. 2025;79:1160-3. https://pubmed.ncbi.nlm.nih.gov/40908328/
16. Bidesie J, et al. Obesity (Silver Spring). 2026;34(Suppl 2):64-9. https://pubmed.ncbi.nlm.nih.gov/42399213/
17. Wegovy prescribing information (rev. 06/2026): https://www.novo-pi.com/wegovy.pdf
18. Zepbound prescribing information: https://uspl.lilly.com/zepbound/zepbound.html
19. Ozempic prescribing information: https://www.novo-pi.com/ozempic.pdf
20. Mounjaro prescribing information: https://uspl.lilly.com/mounjaro/mounjaro.html
21. NIH Office of Dietary Supplements fact sheets (vitamin D, calcium, magnesium, thiamin): https://ods.od.nih.gov/factsheets/list-all/
22. American Academy of Dermatology, hair shedding: https://aad.org/hair-shedding
23. Institute of Medicine, Dietary Reference Intakes (fiber), 2005: https://nap.nationalacademies.org/catalog/10490

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#PCOS #GLP1 #PMOS #Semaglutide #Tirzepatide

Not losing weight on GLP-1 with PCOS? You're not imagining it, and it's not a willpower problem. In this video, I explain why semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) can stall in women with PCOS, now officially renamed PMOS (polyendocrine metabolic ovarian syndrome), and the 4 things doctors do to get weight loss moving again.

You'll learn the 3 hormonal roadblocks behind a PCOS stall (high insulin, androgens and belly fat, and your own GLP-1 system), why standard dosing often isn't enough, how tirzepatide compares with semaglutide, when metformin or inositol makes sense, which labs to track (fasting insulin, HOMA-IR, free testosterone, SHBG, TSH, A1c and lipids), and how to tell your treatment is working even when the scale isn't.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

Timestamps

00:00 Why GLP-1 weight loss stalls with PCOS
00:55 About me
01:21 PCOS is now PMOS: why the name changed
02:36 Insulin resistance in PCOS: the numbers
03:12 Roadblock #1: Hyperinsulinemia
04:44 Roadblock #2: Androgens and belly fat
06:10 Muscle: a shortcut around insulin resistance
06:57 Roadblock #3: Your own GLP-1 system
07:55 Why standard GLP-1 dosing stalls
09:11 Metabolic adaptation and normal plateaus
09:51 Fix #1: Right drug, right dose
10:36 Tirzepatide vs semaglutide (and PCOS data)
11:39 Retatrutide
11:56 Pregnancy and birth control on GLP-1s
12:22 Fix #2: Metformin, combination therapy and inositol
13:57 Fix #3: Labs to track, not just the scale
15:33 Fix #4: Body composition and protecting muscle
16:39 Non-scale wins to watch
17:09 GLP-1 Masterclass
17:30 Summary and what happens if you stop

References

1. Teede HJ, et al. 2023 International Evidence-based Guideline for PCOS. J Clin Endocrinol Metab. 2023;108(10):2447-2469.
2. PCOS renamed PMOS. The Lancet, May 12, 2026; Monash/MCHRI terminology summary, 2026.
3. Stepto NK, et al. Hum Reprod. 2013;28(3):777-784.
4. Cassar S, et al. Hum Reprod. 2016;31(11):2619-2631.
5. Nestler JE. Semin Reprod Endocrinol. 1997;15(2):111-122.
6. O'Reilly MW, et al. J Clin Endocrinol Metab. 2017;102(9):3327-3339.
7. Zhu S, et al. Front Endocrinol. 2021;12:697223.
8. Karolinska Institutet doctoral thesis on adipocyte lipolysis in PCOS.
9. Moro C, et al. J Clin Endocrinol Metab. 2009;94(7):2579-2586.
10. Aydin K, et al. Clin Endocrinol. 2014;81(4):588-592.
11. Güneşli I, et al. Endocrine Abstracts. 2025;110:RC5.2.
12. An impaired GLP-1 response is associated with prediabetes in PCOS with obesity. PMC6833370.
13. Glintborg D, et al. Endocr Connect. 2017;6(4):267-277.
14. Wegovy (semaglutide) US Prescribing Information, including Wegovy HD 7.2 mg (FDA, 2026).
15. Zepbound (tirzepatide) US Prescribing Information.
16. Carmina E, Longo RA. J Clin Med. 2023;12(18):5921.
17. Alawami F, et al. Ir J Med Sci. 2026;195(1):131-136.
18. Fothergill E, et al. Obesity. 2016;24(8):1612-1619.
19. Thomas MK, et al. J Clin Endocrinol Metab. 2021;106(2):388-396.
20. Tirzepatide vs semaglutide on beta-cell function and insulin sensitivity. J Clin Endocrinol Metab. 2024;109(12):3046-3054.
21. Aronne LJ, et al. SURMOUNT-5. N Engl J Med. 2025;393(1):26-36.
22. Clift AK, et al. J Endocr Soc. 2026;10(9):bvag177.
23. PERIODS trial (tirzepatide in PCOS). ClinicalTrials.gov NCT07326111.
24. Jastreboff AM, et al. TRIUMPH-1 (retatrutide). N Engl J Med. 2026.
25. Jensterle M, et al. Exp Ther Med. 2016;11(4):1194-1200.
26. Zhang W, et al. Metab Target Organ Damage. 2026;6:10.
27. Fitz V, et al. J Clin Endocrinol Metab. 2024;109(6):1630-1655.
28. Matthews DR, et al. Diabetologia. 1985;28(7):412-419.
29. Ding X, et al. Front Endocrinol. 2018;9:700.
30. Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002; Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216.
31. Jensterle M, et al. Front Endocrinol. 2024;15:1366940.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Testosterone #TRT #LowTestosterone #GLP1 #weightloss

Is “male menopause” real, and do you actually need testosterone therapy? As an internal medicine and obesity medicine physician, I break down what the research really shows about low testosterone after 50, including:

How common true late-onset hypogonadism actually is (hint: far less than the ads suggest)
Why excess weight is the #1 fixable cause of low testosterone, and how GLP-1s like Ozempic and Mounjaro may help your own testosterone come back
How to get tested properly (morning, fasting, repeated)
What TRT can and can’t do, according to the Testosterone Trials
What the TRAVERSE trial showed about heart safety, plus the side effects that did go up
The newest FDA label changes and the HHS proposal
A simple 5-question checklist to work through with your doctor before you ever start TRT

📘 FREE GLP-1 Diet Cookbook (high-protein meals for a smaller appetite): https://drmohammedpaika.com/newsletter

🎓 GLP-1 Masterclass (calorie and protein targets, side effects, and a 12-week home strength program): https://drmohammedpaika.com

This video is for educational purposes only and is not medical advice. Talk to your own doctor before starting, stopping, or changing any medication.

TIMESTAMPS
0:00 Is low testosterone really the answer?
1:34 Is “male menopause” even real?
3:13 The biggest driver of low testosterone: weight
4:04 How GLP-1s may raise your own testosterone
5:00 The other side: semaglutide and low T
6:03 How to know if you actually have low testosterone
7:28 What TRT really does: the Testosterone Trials
8:54 Is testosterone safe for your heart? (TRAVERSE)
10:29 FDA label changes and the HHS proposal
11:04 On a GLP-1 and testosterone at the same time?
12:06 Should everyone consider hormone therapy?
13:08 5 questions to ask before starting TRT
14:24 What to watch next

📚 REFERENCES

Gray A, et al. Massachusetts Male Aging Study. J Clin Epidemiol. 1991;44:671-684.
Feldman HA, et al. Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589-598.
Wu FCW, et al. European Male Ageing Study: late-onset hypogonadism. N Engl J Med. 2010;363:123-135.
Corona G, et al. Weight loss and obesity-associated hypogonadism (meta-analysis). Eur J Endocrinol. 2013;168:829-843.
Portillo-Canales S, Dhindsa S, et al. Incretin-based drugs and testosterone in men. ENDO 2025 abstract RF27-03; Endocr Pract. 2026;32:696-703.
Liao B, Able C, et al. Semaglutide and hypogonadism/ED in non-diabetic men. SMSNA 2023 abstract 157; Able C, et al. Int J Impot Res. 2024.
Bhasin S, et al. Testosterone therapy in men with hypogonadism: Endocrine Society guideline. J Clin Endocrinol Metab. 2018;103:1715-1744.
Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423-432.
Snyder PJ, et al. Effects of testosterone treatment in older men (Testosterone Trials). N Engl J Med. 2016;374:611-624.
Qaseem A, et al. Testosterone treatment in men with age-related low testosterone: ACP guideline. Ann Intern Med. 2020;172:126-133.
Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). N Engl J Med. 2023;389:107-117.
Snyder PJ, et al. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390:203-211.
U.S. FDA. Class-wide labeling changes for testosterone products. Feb 28, 2025.
U.S. HHS. Request to update testosterone replacement therapy labeling. June 18, 2026 (proposed).
U.S. FDA. Removal of boxed warnings on menopausal hormone therapy. Nov 2025.
Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002.
Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Microdosing #Zepbound #Ozempic #WeightLossMaintenance

Microdosing Zepbound & Ozempic: How Low Can You Go and Still Keep the Weight Off?

You hit your goal weight. Now the question is: do you have to stay on this dose forever? More and more people are cutting their GLP-1 dose to a fraction or stretching their shots to every 10 to 14 days, hoping to save money, cut side effects, and keep the weight off.

I'm Dr. Mohammed Paika, a board-certified internal medicine and obesity medicine physician and practicing hospitalist. In this video I break down what the research actually shows about lower-dose GLP-1 maintenance, and what it doesn't show yet.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

TIMESTAMPS
0:00 Do I have to stay on this dose forever?
1:24 The rebound: what happens when you stop
2:49 Why microdosing is trending now
4:01 What is microdosing? The minimal effective dose
5:02 Two approaches: dose reduction vs. interval spacing
6:01 What happens at lower doses
7:35 Muscle preservation
9:14 What the evidence says: SURMOUNT-MAINTAIN
12:03 Why the weight comes back: the set point
13:35 Why people want a lower dose: cost, supply, side effects
14:16 The 4 risks of going too low
17:06 My step-down framework
18:38 How low can you go? The bottom line

REFERENCES
1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.
3. SURMOUNT-4 post hoc analysis of weight regain. JAMA Intern Med. 2025.
4. Evidation. Real-world GLP-1 dosing behaviors (preliminary survey). December 2025.
5. Bickel CS, Cross JM, Bamman MM. Exercise dosing to retain resistance training adaptations in young and older adults. Med Sci Sports Exerc. 2011;43(7):1177-1187.
6. Wegovy (semaglutide), Ozempic (semaglutide) and Zepbound (tirzepatide) US prescribing information.
7. Hackensack Meridian Health. Is microdosing GLP-1s safe? May 2026.
8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.
9. Nauck MA, et al. Rapid tachyphylaxis of the GLP-1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.
10. O'Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649.
11. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
12. Wilding JPH, et al. STEP 1 body composition (DXA) substudy. J Endocr Soc. 2021;5(Suppl 1):A16-A17.
13. Look M, et al. SURMOUNT-1 body composition (DXA) substudy. Diabetes Obes Metab. 2025.
14. SURMOUNT-MAINTAIN. Tirzepatide maximum dose vs. 5 mg vs. placebo for weight maintenance. Lancet. May 2026.
15. Gudbergsen H, et al. Semaglutide with a digital weight-management program in Denmark (Embla), lowest effective dose. 2025.
16. Embla semaglutide tapering study. European Congress on Obesity. 2024.
17. ClinicalTrials.gov NCT07783854. Randomized dose-tapering regimen of semaglutide for weight-loss maintenance.
18. Eli Lilly. ATTAIN-MAINTAIN topline results (orforglipron). December 2025.
19. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604.
20. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612-1619.
21. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. 2025.
22. Eli Lilly. Zepbound KwikPen instructions for use and FAQ (priming). 2026.
23. US FDA. Dosing errors with compounded semaglutide. July 26, 2024.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #Mounjaro #GLP1 #Tirzepatide #WeightLossDoctor

Should you split your weekly Ozempic, Wegovy, Mounjaro, or Zepbound shot into two smaller doses? Lots of you have asked me about this in the comments. People split their dose to ease the nausea in the first few days and keep food noise down late in the week. In this video, I explain what the pharmacokinetics predict, what the clinical trials did and didn’t test, and the hidden risks most people never hear about.

As an obesity medicine physician, I walk you through half-life, steady state, peak and trough levels, and a simple model of what splitting does to your drug levels. Then I cover the safer, approved ways your doctor can smooth out your week instead.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

⚠️ This video is for education only and is not personal medical advice. Don’t change your dose, your schedule or your device without talking to the clinician who prescribes it.

TIMESTAMPS
0:00 Should you split your weekly GLP-1 dose?
1:17 Why people split their dose: the peak and the trough
2:56 Half-life and steady state
3:27 What splitting does to your drug levels
5:11 Side effects: the peak or the dose increase?
6:09 What the clinical trials actually tested
7:52 Plausible vs. proven
8:21 Hidden risks: pens and vials
9:16 Compounded vials and dosing errors
10:44 Strategy 1: Slow the titration
11:23 Strategy 2: Find your lowest effective dose
11:56 Strategy 3: Eat around injection day
12:35 Strategy 4: Timing and short-term support
12:58 Strategy 5: Change the molecule
13:45 The verdict
14:14 3 questions for your doctor

REFERENCES

Wegovy (semaglutide) US Prescribing Information, Novo Nordisk. https://www.novo-pi.com/wegovy.pdf
Zepbound (tirzepatide) US Prescribing Information, Eli Lilly. https://medlibrary.org/lib/rx/meds/zepbound/page/5/
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg. Diabetes Obes Metab. 2022;24:94-105.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
Aronne LJ, et al. Tirzepatide vs. semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.
O’Neil PM, et al. Semaglutide vs. liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649.
Frias JP, et al. Tirzepatide dose-escalation regimens. Diabetes Obes Metab. 2020;22:938-946.
Huang KP, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature. 2024;632:585-593.
Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58:7370-7380.
Cengiz A, et al. Alternative dosing regimens of GLP-1 receptor agonists. Diabetes Obes Metab. 2025;27:2251-2258.
Ji L, et al. GZR18 once-weekly or bi-weekly dosing: phase 1b/2a trial. Cell Rep Med. 2026;7:102743.
FDA. Dosing errors associated with compounded injectable semaglutide (July 2024). https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
ISMP. Errors possible when microdosing (counting clicks) to dose weight loss medicines (2025). https://www.consumermedsafety.org/safety-articles/errors-possible-when-microdosing-counting-clicks-to-dose-weight-loss-medicines
Lilly Medical: Zepbound single-dose vial and KwikPen guidance. https://medical.lilly.com
America’s Poison Centers semaglutide call data, as reported by CNN/ABC7 (Dec 2023). https://abc7ny.com/fda-poison-control-centers-weight-loss-drug-diabetes/14178159/
Foundayo (orforglipron) US Prescribing Information, Eli Lilly.
Ryan H, et al. OxyContin’s 12-hour problem. Los Angeles Times. 2016.

Modeled peak and trough figures come from a simple one-compartment model built on label half-lives. They are illustrative estimates, not blood levels measured in a trial.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#FoodNoise #GLP1 #Ozempic #WeightLoss #ObesityMedicine

Can't stop thinking about food, even right after a full meal? That constant chatter has a name: food noise. I explain what it is, why GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound quiet it, and why it often returns when people stop them.

You'll learn the 2 drivers behind it, a simple test to tell real hunger from food noise, and 9 evidence-based strategies to turn it down, with or without medication. Every claim is referenced below.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
0:00 Can't stop thinking about food?
1:32 Food noise vs. real hunger
2:02 Why GLP-1s made food noise famous
2:41 What happens when you stop semaglutide
3:02 Your brain's 2 appetite systems
4:13 Driver 1: Physical
4:24 Pattern 1: Eating too little, too early
7:20 Driver 2: Psychological
7:30 Trigger 1: Habit (the Netflix effect)
9:02 How sleep and stress turn up the volume
9:29 The plain-food test: hunger or noise?
9:57 9 strategies to quiet food noise
10:07 1. Protein-forward breakfast
10:31 2. Eat your carbs last
10:58 3. Protect your sleep
11:16 4. Edit your food cues
11:39 5. Plan and prep once a week
13:27 Your 7-day experiment
13:42 When food noise is still loud: GLP-1 medications
14:15 4 important caveats
15:11 When it's more than noise

REFERENCES
1. Hayashi 2023, Nutrients: https://pubmed.ncbi.nlm.nih.gov/38004203/
2. Blundell 2017, Diabetes Obes Metab: https://pmc.ncbi.nlm.nih.gov/articles/PMC5573908/
3. van Bloemendaal 2014, Diabetes 63(12):4186
4. Wilding 2022, Diabetes Obes Metab: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/
5. Lutter 2009, J Nutr: https://pubmed.ncbi.nlm.nih.gov/19176746/
6. Berridge 2009, Physiol Behav: https://pmc.ncbi.nlm.nih.gov/articles/PMC2717031/
7. Boswell 2016, Obes Rev: https://canlab.yale.edu/sites/default/files/boswel-kober_2016_obesityreviews.pdf
8. Wood & Neal 2007, Psychol Rev 114(4):843
9. Keys 1950, The Biology of Human Starvation (Minnesota Starvation Experiment)
10. Sumithran 2011, NEJM: https://pubmed.ncbi.nlm.nih.gov/22029981/
11. Rolls 2017, Nutr Bull: https://pubmed.ncbi.nlm.nih.gov/29151813/
12. Dennis 2010, Obesity: https://pubmed.ncbi.nlm.nih.gov/19661958/
13. World Health Organization 2023, Guideline on non-sugar sweeteners (May 15, 2023)
14. Ludwig 1999, Pediatrics: https://pubmed.ncbi.nlm.nih.gov/10049982/
15. Lennerz 2013, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/23803881/
16. Weigle 2005, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/16002798/
17. Hall 2019, Cell Metab: https://pubmed.ncbi.nlm.nih.gov/31105044/
18. Leidy 2015, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/25926512/
19. Neal et al. 2011, Pers Soc Psychol Bull 37(11):1428
20. Tomova 2020, Nat Neurosci: https://dspace.mit.edu/handle/1721.1/138313
21. Spiegel 2004, Ann Intern Med: https://pubmed.ncbi.nlm.nih.gov/15583226/
22. Hoertel 2014, Nutr J: https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-13-80
23. Leidy 2013, Am J Clin Nutr: https://pmc.ncbi.nlm.nih.gov/articles/PMC3718776/
24. Tasali 2022, JAMA Intern Med: https://pubmed.ncbi.nlm.nih.gov/35129580/
25. Hunter 2018, Appetite: https://pubmed.ncbi.nlm.nih.gov/29183701/
26. Ducrot 2017, Int J Behav Nutr Phys Act: https://pubmed.ncbi.nlm.nih.gov/28153017/
27. Lieberman 2007, Psychol Sci: https://pubmed.ncbi.nlm.nih.gov/17576282/
28. Zaccaro 2018, Front Hum Neurosci: https://pubmed.ncbi.nlm.nih.gov/30245619/
29. Gollwitzer & Sheeran 2006, Adv Exp Soc Psychol 38:69
30. Taylor & Oliver 2009, Appetite 52(1):155
31. Ledochowski 2015, PLoS One: https://pmc.ncbi.nlm.nih.gov/articles/PMC4356559/
32. Buffey 2022, Sports Med: https://pubmed.ncbi.nlm.nih.gov/35147898/
33. Wilding 2021, NEJM (STEP 1): https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
34. Hudson 2007, Biol Psychiatry: https://pubmed.ncbi.nlm.nih.gov/16815322/
35. Tataranni 1996, Am J Physiol: https://pubmed.ncbi.nlm.nih.gov/8770026/
36. Shukla 2015, Diabetes Care: https://pmc.ncbi.nlm.nih.gov/articles/PMC4876745/

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Menopause #Tirzepatide #Semaglutide #WeightLoss

Not losing weight on a GLP-1 after menopause? You’re not imagining it, but your body isn’t broken and the medication hasn’t stopped working. In this video, I’m Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. I break down what the research really shows about GLP-1s like tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) after menopause.

You’ll learn what menopause does to fat, muscle and metabolism, and how much weight women actually lose at each stage of menopause in the clinical trials. I’ll show you why real-world results can lag, what the newest hormone therapy studies show and why they don’t prove cause and effect, and how to protect your muscle and bones. I’ll also walk you through the 5-step plan I use with my midlife patients.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
0:00 Why weight loss feels harder after menopause
1:56 What menopause does to your body
4:15 Do GLP-1s still work after menopause?
7:12 Why it feels harder in real life
9:06 Hormone therapy and GLP-1s: what the data shows
11:21 Free GLP-1 Diet Cookbook
11:44 Protecting your muscle and bones
13:42 GLP-1 Masterclass
14:12 The 5-step midlife GLP-1 plan
15:35 A real viewer example
16:41 Final thoughts

📚 REFERENCES
Greendale GA, et al. Changes in body composition and weight during the menopause transition (SWAN). JCI Insight. 2019;4(5):e124865.
Lovejoy JC, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32(6):949-958.
Pontzer H, et al. Daily energy expenditure through the human life course. Science. 2021;373(6556):808-812.
Karppinen JE, et al. Age but not menopausal status is linked to lower resting energy expenditure. J Clin Endocrinol Metab. 2023;108(11):2789-2797.
Thomson ZO, et al. Weight loss outcomes in premenopausal versus postmenopausal women during behavioral weight loss interventions. Menopause. 2021;28(3):337-346.
Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage (SURMOUNT post hoc). Obesity. 2025;33:851-860.
García-Pérez LE, et al. Tirzepatide weight reduction by sex: SURMOUNT-1 to -4 post hoc. Presented at EASD 2024.
Castaneda R, et al. Sex, not age, predicts weight loss outcomes with tirzepatide. Obesity. 2026;34(Suppl 2):132-145.
Huvinen E, et al. Body weight loss with semaglutide 7.2 mg is independent of menopausal status (STEP UP post hoc). Presented at the European Congress on Obesity, 2026.
Castaneda R, et al. Impact of reproductive stage and menopausal hormone therapy on weight loss outcomes with tirzepatide. Presented at The Menopause Society Annual Meeting, 2025.
Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010;153(7):435-441.
Hurtado MD, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31:266.
Castaneda R, et al. Menopause hormone therapy and tirzepatide-associated weight loss in postmenopausal women. Lancet Obstet Gynaecol Womens Health. 2026;2(2):e118-e128.
Hurtado MD, et al. Semaglutide reduces body weight regardless of menopause status (STEP and OASIS 4 post hoc). Presented at ObesityWeek, 2025.
Papadakis GE, et al. Menopausal hormone therapy is associated with reduced total and visceral adiposity (OsteoLaus). J Clin Endocrinol Metab. 2018;103(5):1948-1957.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025.
Jensen SBK, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Netw Open. 2024;7(6):e2416775.
Watson SL, et al. High-intensity resistance and impact training in postmenopausal women with low bone mass (LIFTMOR). J Bone Miner Res. 2018;33(2):211-220.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Wegovy #Zepbound #WeightLoss

Why GLP-1 Medications Cause Extreme Fatigue (And How to Fix Low Energy)

Are you exhausted on Ozempic, Wegovy, Mounjaro, or Zepbound? You’re not imagining it. Fatigue is listed in the prescribing information, and it’s one of the most common complaints I see in the comments.

In this video, I’m Dr. Mohammed Paika, an internal medicine and obesity medicine physician. I break down the 4 biological reasons GLP-1 medications can leave you drained: unintentional undereating, quiet dehydration, the drug’s effects on the brain, and nutrient deficiencies like low iron and B12. Then I walk you through 4 practical fixes: a calorie and protein floor, a hydration plan that goes beyond plain water, the blood work to ask your doctor for, and how to talk to your prescriber about dose and titration. I finish with the warning signs that mean you need to be seen right away.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

This video is for education only and is not personal medical advice. Talk to your own clinician before changing your diet, fluids, supplements, or medication.

TIMESTAMPS
0:00 Why you feel exhausted on a GLP-1
2:00 Who I am and why I made this video
3:09 Is the drug toxic? What the trials show
4:35 Cause #1: Running on empty
7:43 Cause #2: The thirst signal goes quiet
10:35 Cause #3: The drug talks to your brain
12:52 Cause #4: The deficiency nobody tests for
15:27 Fix #1: Set a calorie and protein floor
18:01 Fix #2: Hydrate beyond plain water
19:44 Fix #3: The blood work to ask for
21:10 Fix #4: Slow the dose down, don’t quit
22:36 Red flags: when to get seen urgently

REFERENCES

Wegovy (semaglutide) Prescribing Information. FDA, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
Zepbound (tirzepatide) Prescribing Information. https://uspl.lilly.com/zepbound/zepbound.html; Jastreboff AM, et al. N Engl J Med. 2022;387:205–216 (SURMOUNT-1).
Friedrichsen M, et al. Diabetes Obes Metab. 2021;23:754–762. https://doi.org/10.1111/dom.14280
Prado CM, et al. Lancet Diabetes Endocrinol. 2024;12:785–787. https://doi.org/10.1016/S2213-8587(24)00272-9
Winzeler B, et al. J Clin Invest. 2021;131:e151800. https://jci.org/articles/view/151800
Gutzwiller JP, et al. Digestion. 2006;73:142–150.
Gabery S, et al. JCI Insight. 2020;5:e133429. https://insight.jci.org/articles/view/133429
Butsch WS, et al. Obesity Pillars. 2025;15:100186. https://doi.org/10.1016/j.obpill.2025.100186
Mozaffarian D, et al. Am J Clin Nutr. 2025;122:344–367. https://doi.org/10.1016/j.ajcnut.2025.04.023
Aroda VR, et al. J Clin Endocrinol Metab. 2016;101:1754–1761. https://pmc.ncbi.nlm.nih.gov/articles/PMC4880159
Westerterp-Plantenga MS, et al. J Appl Physiol. 1999;87:391–399. https://pubmed.ncbi.nlm.nih.gov/10409600/
Paika MK. GLP-1 Masterclass; The Weight Equation; GLP-1 Diet Cookbook. https://drmohammedpaika.com

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #GLP1 #Semaglutide #AlcoholUseDisorder #WeightLoss

People on Ozempic and Wegovy are reporting a side effect that isn't on the label: they're losing interest in alcohol. Is it real, or just nausea? As an internal medicine and obesity medicine physician, I work this up like an unexplained finding in a hospital patient. We'll look at the patient reports and real-world data, consider every possible explanation, read the newest trials (including the 2026 Lancet trial), and finish with a practical plan.

In this video you'll learn:
Why GLP-1 drugs may turn down cravings, and what "food noise" really is
What the Lancet, JAMA Psychiatry and earlier trials actually found
Why the first human trial failed, and how it shaped the one that worked
What we still don't know before this becomes a standard treatment
5 safety rules if you drink while on a GLP-1

TIMESTAMPS
0:00 – A strange answer on the admission form
1:44 – What patients are reporting (and what the data shows)
3:20 – Why this matters: the alcohol treatment gap
4:43 – Three possible explanations
7:43 – How GLP-1s act on the brain: the two buttons
10:36 – Protecting your muscle on a GLP-1
11:17 – The 2026 Lancet trial
12:43 – The lab trial: what changed and what didn't
13:53 – The trial that failed, and what it taught us
15:33 – Animal research foundations
16:28 – Would I prescribe it for alcohol today?
18:46 – 5 rules before your next drink on a GLP-1
20:30 – Treatments that already work
21:46 – Final thoughts and resources

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

REFERENCES
Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. Lancet. 2026;407(10540):1687–1698. https://doi.org/10.1016/S0140-6736(26)00305-3
Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395–405.
Klausen MK, et al. Exenatide once weekly for alcohol use disorder. JCI Insight. 2022;7(19):e159863. https://insight.jci.org/articles/view/159863
Lähteenvuo M, et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025;82(1):94–98.
Wang W, Volkow ND, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder. Nat Commun. 2024;15:4548. https://doi.org/10.1038/s41467-024-48780-6
Quddos F, et al. Physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity. Sci Rep. 2025. https://doi.org/10.1038/s41598-025-17927-w
Suchankova P, et al. The GLP-1 receptor as a potential treatment target in alcohol use disorder. Transl Psychiatry. 2015;5:e583. https://www.nature.com/articles/tp201568
Thomsen M, et al. GLP-1 analogs and alcohol intake in vervet monkeys. Psychopharmacology. 2019;236:603–611.
Aranäs C, et al. Semaglutide reduces alcohol intake and relapse-like drinking in rats. eBioMedicine. 2023;93:104642.
Leggio L, et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023;29:2993–2995.
Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. 2016;71(8):670–679.
Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374:363–371.
Wilding JPH, et al. Weight regain after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
Jonas DE, et al. Pharmacotherapy for adults with alcohol use disorders. JAMA. 2014;311(18):1889–1900.
Han B, et al. Use of medications for alcohol use disorder in the US. JAMA Psychiatry. 2021;78(8):922–924.
World Health Organization. Global status report on alcohol and health. 2024.
U.S. Surgeon General. Alcohol and Cancer Risk Advisory. 2025.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Retatrutide #GLP3 #WeightLoss #GLP1 #ObesityMedicine

How long does retatrutide actually stay in your system? Retatrutide, the triple-hormone drug people call "GLP-3" or "reta," has a half-life of about 6 days. That one number explains when side effects hit and why the dose has to climb slowly. It also explains why a short pause before surgery may not be enough, and why the drug lingers for about a month after your last shot.

I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. In this video, I walk you through the 4 clocks retatrutide sets in your body and what the phase 3 trials really show, including up to 30.3% weight loss. You'll learn about the side effects people aren't talking about, like changes in skin sensation and heart rate. I also explain why the "research use only" vials sold online are a serious risk. Retatrutide is not FDA-approved. The regulated routes are a clinical trial, Lilly's limited early access program (through your doctor) or waiting for approval.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
00:00 The ER patient who "wasn't taking anything"
01:42 What retatrutide is: 3 signals instead of 2
02:34 What the trials show
03:20 Is retatrutide FDA-approved? How people get it legally
04:02 Retatrutide's half-life: about 6 days
04:27 Why it lasts so long
05:07 Clock 1: the 7-day clock and side effects
06:13 The new side effect: dysesthesia
06:52 Heart rate and heart safety
07:30 Missed dose: there's no official rule
08:11 Clock 2: building up to steady state
08:50 How the trials raised the dose
09:43 Why vials make dosing dangerous
10:34 Clock 3: how long retatrutide stays in your system
11:31 What changes how fast you clear it
12:26 Why side effects don't stop when you stop
12:57 Surgery, endoscopy and sedation
13:42 Pregnancy and contraception
14:15 The vial problem: "research use only"
14:57 What's really in the vial?
15:41 My position as your doctor
17:11 Clock 4: what happens when you stop
17:37 Why your body defends its old weight
18:21 What the stopping data shows
18:55 My own weight-regain story
19:42 Muscle is the real stake
20:31 The plan
21:27 Protecting your muscle on GLP-1s

REFERENCES
(FULL LIST AVAILABLE ON REQUEST)

Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400:1869–1881. https://www.sciencedirect.com/science/article/abs/pii/S0140673622020335
Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Eli Lilly and Company. Retatrutide TRIUMPH-4 phase 3 results. December 11, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 results; BLA planned Q1 2027. July 23, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
Sanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. https://www.nature.com/articles/s41591-024-03018-2
Axios. Unapproved obesity drug spawns a black market frenzy. August 24, 2026. https://www.axios.com/2026/08/24/unapproved-obesity-drug-spawns-a-black-market-frenzy
The Partnership for Safe Medicines. The retatrutide black market: patient safety groups warn of growing risks. August 2026. https://www.safemedicines.org/2026/08/reta-groups-warn-understudied-drugs.html
Finnrick. Retatrutide testing results (accessed October 2026). https://www.finnrick.com/products/retatrutide

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #WeightLoss #Ozempic #Mounjaro #ObesityMedicine

Not losing weight on a GLP-1? The problem usually isn't you, and it usually isn't the medication either. It's the variables nobody checked.

I'm Dr. Mohammed Paika, a physician board-certified in Internal Medicine and Obesity Medicine. I've spent about 15 years as a hospitalist, and I'm also a certified personal trainer and nutrition coach. In this video, I walk you through 8 evidence-based reasons the scale can stall on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), plus a bonus. They range from diabetes and insulin resistance to medications that quietly cause weight gain, eating too little, muscle loss, sleep apnea and dose problems. At the end, I share my 4-question test to tell whether your GLP-1 is working, stalling or needs to be changed.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

⏱️ TIMESTAMPS
0:00 Why your GLP-1 isn't working (the 2 a.m. patient)
1:47 Reason 1: Your starting point was different
3:47 Reason 2: Diabetes, insulin resistance and PCOS
5:13 Reason 3: Medications quietly working against you
6:57 Reason 4: You're eating too little, not too much
8:47 Reason 5: The quiet calorie creep
10:07 Free GLP-1 Diet Cookbook
10:33 Reason 6: You're losing muscle, and the scale can't tell you
12:29 Reason 7: The exercise myth, and what works instead
14:06 GLP-1 Masterclass
14:41 Reason 8: Sleep, stress and sleep apnea
15:55 Bonus: Dose, timing, injection site and refills
17:35 The 4-question test: is your GLP-1 working?
19:36 What to watch next

📚 REFERENCES

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Davies M, et al. Semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
Garvey WT, et al. Tirzepatide in people with obesity and type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
Look M, et al. Body composition changes with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025.
Mosenzon O, et al. Clinically relevant weight loss independent of early response to semaglutide 2.4 mg (STEP 4). J Endocr Soc. 2021;5(Suppl 1).
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
Lichtman SW, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med. 1992;327:1893-1898.
Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010;153:435-441.
Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24:1612-1619.
LaForgia J, et al. Effects of exercise intensity and duration on excess post-exercise oxygen consumption. J Sports Sci. 2006;24:1247-1264.
Pontzer H, et al. Constrained total energy expenditure and metabolic adaptation to physical activity. Curr Biol. 2016;26:410-417.
Greendale GA, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4:e124865.
Magkos F, et al. Effects of moderate and subsequent progressive weight loss on metabolic function. Cell Metab. 2016;23:591-601.
Wegovy (semaglutide) and Zepbound (tirzepatide) U.S. Prescribing Information.
Paika MK. GLP-1 Masterclass. 2026.
Paika MK. The Weight Equation: A Physician's Guide to the Science and Treatment of Obesity. 2026.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Tirzepatide #Mounjaro #Zepbound #GLP1 #WeightLoss

How long does tirzepatide (Mounjaro, Zepbound) actually stay in your system? It's not 5 days. In this video, I explain tirzepatide's half-life using 4 clocks it sets in your body. Those clocks explain when side effects hit and what to do if you miss a dose. They also explain why a 1-week pause before surgery may not be enough, why the birth control rule is 4 weeks, and how long the drug takes to clear after your last shot.

Then we get to the clock that matters most: what happens after you stop. You'll see what the SURMOUNT-4 trial found about weight regain and why muscle loss is the real risk. I'll also share how I regained 45 pounds when my own structure disappeared, and the 2 paths that protect your results.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
00:00 Why "it's gone in 5 days" is wrong
01:26 What tirzepatide is and how it works
02:25 Half-life explained
02:59 Why it lasts so long: albumin binding
03:48 Clock 1: the 7-day clock
04:18 Side effects: when they hit and how to ease them
05:47 Why food noise returns at the end of the week
06:14 Missed a dose? The 96-hour rule
07:16 Clock 2: the 4-week clock and steady state
08:06 Why your dose goes up in 2.5 mg steps
09:05 Birth control: the 4-week rule
10:09 Clock 3: how long tirzepatide stays in your system
10:56 What makes clearance faster or slower
12:39 Why severe side effects don't stop when you stop
13:42 Surgery, colonoscopy and sedation
15:07 Pregnancy planning
15:35 Will it show up on a drug test?
16:12 Clock 4: what happens when you stop
16:46 Why your body fights weight loss
17:36 SURMOUNT-4: stopping vs staying on
17:58 My own weight-regain story
18:48 The muscle problem
19:51 The plan: 2 good paths
21:17 Protecting your muscle on GLP-1s

REFERENCES
Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. https://pi.lilly.com/us/zepbound-uspi.pdf
Kindel TL, et al. Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period. 2024. https://www.cghjournal.org/article/S1542-3565(24)00910-8/fulltext
American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. June 29, 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative
Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. https://jamanetwork.com/journals/jama/fullarticle/2812936
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–1604. https://pubmed.ncbi.nlm.nih.gov/22029981/
Eli Lilly and Company. SURMOUNT-1 results published in The New England Journal of Medicine. 2022. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine
Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36:761–765.
Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612–1619. https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538
Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/
Paika MK. GLP-1 Masterclass; The Weight Equation; Obesity Medicine in Clinical Practice: High-Yield Guide; The Physician's Physique.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #GLP1 #Wegovy #EyeHealth #obesitymedicine

Can Ozempic, Wegovy or Mounjaro make you blind? A viewer asked me this, and it deserves an honest, evidence-based answer. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist.

In this video I review every major study on GLP-1 medications and NAION, a rare "stroke" of the optic nerve:

The Mass Eye and Ear study that sparked the headlines
The larger studies from Denmark, Norway and the US
The randomized trials

I also cover what the European Medicines Agency, the UK's MHRA and the American Academy of Ophthalmology concluded, plus the separate issue of diabetic retinopathy. You'll learn the real risk in actual numbers, who is at higher risk, and a 5-step eye-safety plan, including the one warning sign that means you go to the ER the same day.

TIMESTAMPS
0:00 Can GLP-1s make you blind? A viewer's question
0:58 Who I am and why this matters
1:37 What is NAION? The "stroke" of the optic nerve
3:15 How the alarm started: the Mass Eye and Ear study
4:16 What the bigger studies found
6:13 GLP-1 Masterclass
6:51 What regulators and eye specialists concluded
8:44 Putting the risk in perspective
9:28 The other eye issue: diabetic retinopathy
10:41 Free GLP-1 Diet Cookbook
11:01 Who is at higher risk?
12:16 The 5-step eye-safety plan
14:10 What to watch next

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

REFERENCES
StatPearls: Nonarteritic anterior ischemic optic neuropathy. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK559045/
Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 1994;14(1):38-44
Hathaway JT, Shah M, Hathaway DB, et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739
Grauslund J, Abou Taha A, Molander LD, et al. Once-weekly semaglutide doubles the five-year risk of NAION in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10:97
Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of NAION: a Danish–Norwegian cohort study. Diabetes Obes Metab. 2025;27(6):3094-3103
Hsu AY, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025. doi:10.1001/jamaophthalmol.2025.0349
Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526327
DeParis SW, et al. GLP-1 receptor agonists and the risk of NAION: a consensus statement by NANOS and the American Academy of Ophthalmology. Ophthalmology. 2026;133(8)
NAION risk with semaglutide: what we know so far (includes Chou et al., 18,657 patients). Eye. 2025. https://www.nature.com/articles/s41433-025-03833-y
Liu Z, Raveendran D, Fourlanos S, et al. Rate and risk of NAION with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis. Ophthalmology. 2026;133:589-598
European Medicines Agency (PRAC). NAION a very rare side effect of semaglutide. June 2025. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
MHRA Drug Safety Update: Semaglutide and risk of NAION. Feb 5, 2026
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232
Centers for Disease Control and Prevention. Diabetes and vision loss
Marso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844
Vilsbøll T, et al. Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897
Leinung M, Patel N, Bettadahalli S, Paika MK, et al. Benefits of short-term professional continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013
Campbell UB, et al. Acute NAION and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12(1):139-151

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Mounjaro #Wegovy #ObesityMedicine

Most people think GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound are just for weight loss. The research tells a much bigger story. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist. In this video I count down 12 evidence-graded health benefits of GLP-1 medications beyond the scale, plus a bonus from the newest cancer research.

You'll learn what the major trials show about your heart, liver, kidneys, blood pressure, sleep apnea, inflammation, alcohol cravings, joint pain and blood sugar. I also cover what the latest Alzheimer's trials actually found. Stay for number 1: a major analysis of the SELECT trial found that about two-thirds of the heart protection wasn't explained by weight loss.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
0:00 Why GLP-1s are about more than weight loss
1:05 Who I am and why this matters
1:56 #12 Blood pressure and blood fats
2:42 #11 Less joint pain, more mobility
3:52 #10 Fewer alcohol cravings
5:00 #9 A healthier liver
5:50 #8 Brain health: the honest version
6:55 How to protect muscle on a GLP-1 + Masterclass
8:42 #7 Sleep apnea and deeper sleep
9:40 #6 Fewer medications and diabetes prevention
10:35 BONUS: GLP-1s and cancer, the newest research
11:38 Free GLP-1 Diet Cookbook
12:03 #5 Quieter food noise and steadier blood sugar
12:57 #4 Protecting your kidneys
13:46 #3 Blood sugar and diabetes control
14:35 #2 Cooling down inflammation
15:27 #1 Protecting your heart and blood vessels

REFERENCES

Deanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements (SELECT analysis). Lancet. 2025. PMID: 41138739
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002
Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure. Lancet. 2021;397:1625-1636
Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). N Engl J Med. 2024;391:1573-1583
Eli Lilly. Retatrutide TRIUMPH-4 topline results (press release, Dec 11, 2025; not yet peer-reviewed). https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
Kosiborod MN, et al. Semaglutide in HFpEF and obesity (STEP-HFpEF). N Engl J Med. 2023;389:1069-1084
Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder. JAMA Psychiatry. 2025;82(4):395-405
Klausen MK, et al. Once-weekly semaglutide vs placebo in alcohol use disorder and comorbid obesity. Lancet. 2026. PMID: 42070571
Younossi ZM, et al. The global epidemiology of NAFLD and NASH. Hepatology. 2023;77(4):1335-1347
Sanyal AJ, et al. Phase 3 trial of semaglutide in MASH (ESSENCE). N Engl J Med. 2025;392:2089-2099
Wang W, et al. Semaglutide and first-time diagnosis of Alzheimer's disease in type 2 diabetes. Alzheimers Dement. 2024;20(12):8661-8672
evoke and evoke+ Investigators. Oral semaglutide in early-stage symptomatic Alzheimer's disease. Lancet. 2026
Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined (S-LITE). N Engl J Med. 2021;384:1719-1730
Heymsfield SB, Aronne LJ, et al. Bimagrumab plus semaglutide for obesity (BELIEVE). Nat Med. 2026. https://www.nature.com/articles/s41591-026-04204-0
Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205
Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3 years). N Engl J Med. 2025;392:958-971
Lauby-Secretan B, et al. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794-798
(complete list available upon request)

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Mounjaro #Tirzepatide #GLP1 #WeightLoss #obesitymedicine

Why do two people on the same Mounjaro dose get completely different results? In this video, I break down a study of more than 3,000 people with type 2 diabetes from the SURPASS 1–4 trials. It looked at who is most likely to lose 15% or more of their body weight on tirzepatide (Mounjaro / Zepbound), and why.

You'll learn the 7 factors that predicted the biggest weight loss. Several of them are things you can change, sometimes before your first injection. I also cover what newer research says about Ozempic and Wegovy, why real-world results are lower than trial results, and the 6-month check-in that tells you whether you're on track.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
0:00 Same drug, very different results
1:15 Mounjaro vs Zepbound vs Ozempic explained
2:19 What the SURPASS study measured
3:32 Factor 1: Sex
4:36 Factor 2: Age (and muscle loss)
6:32 Factor 3: Your starting blood sugar
8:36 Factor 4: Your cholesterol
9:32 GLP-1 Masterclass
10:12 Factor 5: Your other medications
11:41 Factor 6: Dose
12:34 Factor 7: Race and ethnicity
13:29 Surprise: starting weight didn't matter
13:58 Does this apply to Ozempic and Wegovy?
15:26 The limits of this research
16:36 7 steps to improve your odds
19:52 Free GLP-1 Diet Cookbook + what's next

REFERENCES

Małecki MT, Batterham RL, Sattar N, et al. Predictors of ≥15% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1–4. Diabetes Care. 2023;46(12):2292-2299. doi:10.2337/dc23-1135
Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.
Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026;139(7):913-921. doi:10.1016/j.amjmed.2026.03.010
Powell W, Song X, Mohamed Y, et al. Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data. Obesity (Silver Spring). 2023;31(10):2482-2492. doi:10.1002/oby.23859
Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729.
Sattar N, Frühbeck G, Andreelli F, et al. Weight reduction with tirzepatide varied meaningfully by baseline HbA1c category in adults with overweight or obesity and type 2 diabetes in SURMOUNT-2. Diabetes Care. 2025;48(11):e136-e137. doi:10.2337/dc25-1442
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024.
Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S-1329S.
Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025;26(1):e13841.
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Zepbound #Wegovy #weightloss

Losing weight on Wegovy, Ozempic, Zepbound, or Mounjaro? What you eat while you're on it matters more than most people realize. In this video, board-certified internal medicine and obesity medicine physician Dr. Mohammed Paika breaks down the 3 nutrition gaps that show up again and again in GLP-1 patients — protein, fiber, and fluids — and the 10 foods that address them, backed by real research on muscle preservation, gut health, and the GLP-1 pathway itself.

You'll learn why eating less doesn't automatically mean eating well, what the research says about muscle loss on semaglutide and tirzepatide, and exactly which foods to prioritize so you protect your muscle, support your gut, and get more out of your medication — not just a smaller number on the scale.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

Timestamps
0:00 Intro — The Mistake That's Sabotaging Your GLP-1 Results
2:03 Why What You Eat Matters More Than Ever
5:17 The 3 Nutrition Gaps on GLP-1 Medications
7:33 #1 Oats
8:55 #2 Turkey Breast
10:18 #3 Tofu & Edamame
11:35 #4 Tuna & Shrimp
12:44 #5 Quinoa
13:49 #6 Chia Seeds & Flaxseed
15:50 #7 Sweet Potatoes
17:07 #8 High-Protein Milk
18:31 #9 Kefir
20:08 #10 Watermelon, Citrus & Coconut Water
21:33 The One Rule That Ties It All Together
22:06 Final Thoughts

References

Johnson et al. "Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study." Frontiers in Nutrition, 2025;12.
Bikou A, et al. "A systematic review of the effect of semaglutide on lean mass: insights from clinical trials." Expert Opinion on Pharmacotherapy, 2024;25(5):611-619.
Look M, et al. "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study." Diabetes, Obesity and Metabolism, 2025.
Hirasawa T, et al. "Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120." Nature Medicine, 2005;11(1):90-94.
de Jong et al. "Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review." Frontiers in Endocrinology, 2026.
Tolhurst G, et al. "Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2." Diabetes, 2012;61(2):364-371.
Longland TA, et al. "Higher compared with lower dietary protein during an energy deficit..." American Journal of Clinical Nutrition, 2016.
Ogilvie AR, et al. "Higher protein intake during caloric restriction improves diet quality and attenuates loss of lean body mass." Obesity, 2022;30(11).
Nutrition figures throughout: USDA FoodData Central.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #Wegovy #Zepbound #GLP1 #weightlossjourney

Are you taking Wegovy, Ozempic, or Zepbound and feeling like your results have stalled? In this video, board-certified physician Dr. Mohammed Paika breaks down the 5 mistakes that quietly sabotage GLP-1 results — and exactly what to do instead to keep losing fat, protect your muscle, and avoid unnecessary side effects.

Drawing on his experience as a hospitalist and obesity medicine specialist, Dr. Paika walks through dose titration, nutrition, digestion, and lab work — the pieces most people never get told about.

TIMESTAMPS:
0:00 Intro — Why Your Results Might Be Stalling
0:53 Meet Dr. Paika
1:37 Mistake #1: Chasing the Calendar Instead of Your Biology
4:07 Mistake #2: Treating the Medication Like It Replaces the Basics
6:02 Mistake #3: Eating Too Little (and Losing the Wrong Weight)
8:29 Mistake #4: Ignoring What Your Gut Is Telling You
10:47 Mistake #5: Never Checking Your Blood Work
12:27 Final Thoughts + What to Watch Next

REFERENCES:
1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
3. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740-756.
4. Taheri S, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased BMI. PLoS Med. 2004;1(3):e62.
5. Wolfe RR. The underappreciated role of muscle in health and disease. Am J Clin Nutr. 2006;84:475-482.
6. Longland TM, et al. Higher dietary protein during an energy deficit promotes greater lean mass gain and fat loss. Am J Clin Nutr. 2016;103:738-746.
7. Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev. 2007;87:1409-1439.
8. Monami M, et al. Safety issues with GLP-1 receptor agonists (pancreatitis, pancreatic cancer, cholelithiasis). Diabetes Obes Metab. 2017;19(9):1233-1241.
9. American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. 2023.
10. Garvey WT, et al. AACE/ACE comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.